Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 51

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 51
---
 shares of TELO Common Stock in the Merger could on its own have the effect of depressing the market price for TELO Common Stock. In addition, some TELI stockholders may decide not to continue to hold the shares of TELO Common Stock they receive as a result of the Merger, and any such sales of TELO Common Stock could have the effect of depressing the market price for TELO Common Stock. Moreover, general fluctuations in stock markets could have a material adverse effect on the market for, or liquidity of, TELO Common Stock, regardless of the actual operating performance of TELO or the surviving company following the completion of the Merger.

| 27 |

<div align='center'>THE MERGER</div>

This section and the section titled “The Merger Agreement” in this proxy statement describe the material aspects of the Merger, including the Merger Agreement. While TELO believes that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should carefully read this entire proxy statement for a more complete understanding of the Merger and the Merger Agreement, including the Merger Agreement attached as Annex A, the valuation report of TELI Pharmaceuticals, Inc. attached as Annex B, the valuation report for Telomir Pharmaceuticals Inc. is attached as Annex C, and the fairness opinion for the Merger attached as Annex D and the Telomir-1 License Agreement is attached as Annex E to this proxy statement, and the other documents to which you are referred herein. See the section titled “Where You Can Find More Information” in this proxy statement.

Background of the Merger

On December 10, 2024, TELI was incorporated in the state of Delaware. At such point, TELI’s owners and executives had considered separately and independently listing its shares on the Nasdaq Stock Exchange in 2025.

In July 2025, several holders of shares of TELI spoke with Erez Aminov, CEO of TELO about the possibility of TELI becoming a wholly-owned subsidiary of TELO, and forgo its planned stand-alone public offering. These discussions focused on TELO’s interest in acquiring TELI to strengthen and expand its drug development pipeline. TELO believed that the acquisition of TELI, particularly due to expanding the global reach of Telomir-1, would enhance shareholder value. Given the overlapping relationships and common interests between TELO and MIRAL